Skip to main content

Advertisement

SpringerLink
Log in

Allogeneic stem cell transplantation for mantle cell lymphoma—final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO)

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

This study was conducted in order to evaluate allogeneic stem cell transplantation (alloSCT) as consolidation for patients with mantle cell lymphoma (MCL). Patients with MCL were included into two prospective trials OSHO #060 (refractory/relapsed) and #074 (de novo). Induction was rituximab and chemotherapy. Responding patients proceeded to alloSCT. Minimal residual disease was monitored by quantitative RT-PCR detecting either t(11;14) or clonospecific CDR-III regions. In case of circulating lymphoma cells, immunomodulation (cyclosporine A withdrawal, rituximab, donor lymphocyte infusion) was initiated. Thirty-three of 39 patients underwent alloSCT after myeloablative (n = 7) or toxicity-reduced (n = 26) conditioning. Leukocytes engrafted at day +16 (median, range 0–101) and platelets at day +14 (0–142). Acute graft-versus-host disease stages I–II occurred in 42 % and stages III–IV in 15 %. Five patients have relapsed after SCT. The overall mortality after SCT was 24 % (n = 8). Median follow-up after SCT was 2.8 years (range 0.0–10.9). Five-year progression-free survival was 67 %, and overall survival 73 % after SCT. The results were comparable for primary MCL and refractory/relapsed disease as well as for related vs. unrelated SCT. Younger patients had a significantly better outcome than the elderly. AlloSCT is a feasible and promising consolidation therapy for relapsed and refractory disease and an attractive option for young patients with de novo MCL of high risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Barista I, Romaguera JE, Cabanillas F (2001) Mantle-cell lymphoma. Lancet Oncol 2(3):141–148

    Article  CAS  PubMed  Google Scholar 

  2. Bernard M, Gressin R, Lefrere F, Drenou B, Branger B, Caulet-Maugendre S et al (2001) Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia 15(11):1785–1791

    Article  CAS  PubMed  Google Scholar 

  3. Dreyling M, Kluin-Nelemans HC, Bea S, Hartmann E, Salaverria I, Hutter G et al (2011) Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: Report of the 10th Annual Conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma

  4. Williams ME, Swerdlow SH, Meeker TC (1993) Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster. Leukemia 7(9):1437–1440

    CAS  PubMed  Google Scholar 

  5. Rimokh R, Berger F, Delsol G, Digonnet I, Rouault JP, Tigaud JD et al (1994) Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas. Blood 83(7):1871–1875

    CAS  PubMed  Google Scholar 

  6. Mangel J, Leitch HA, Connors JM, Buckstein R, Imrie K, Spaner D et al (2004) Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 15(2):283–290

    Article  CAS  PubMed  Google Scholar 

  7. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M et al (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112(7):2687–2693

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Gianni AM, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S et al (2003) Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 102(2):749–755

    Article  CAS  PubMed  Google Scholar 

  9. Pott C, Schrader C, Gesk S, Harder L, Tiemann M, Raff T et al (2006) Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 107(6):2271–2278

    Article  CAS  PubMed  Google Scholar 

  10. Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM et al (2009) Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 27(26):4365–4370

    Article  CAS  PubMed  Google Scholar 

  11. Kroger N, Hoffknecht M, Dreger P, Kruger W, Zeller W, Krull A et al (1998) Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant 21(1):55–57

    Article  CAS  PubMed  Google Scholar 

  12. Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F et al (2002) Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 99(1):75–82

    Article  CAS  PubMed  Google Scholar 

  13. Martinez C, Carreras E, Rovira M, Urbano-Ispizua A, Esteve J, Perales M et al (2000) Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation. Bone Marrow Transplant 26(6):677–679

    Article  CAS  PubMed  Google Scholar 

  14. Khouri IF, Lee MS, Romaguera J, Mirza N, Kantarjian H, Korbling M et al (1999) Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 10(11):1293–1299

    Article  CAS  PubMed  Google Scholar 

  15. Khouri IF, Champlin RE (2004) Nonmyeloablative stem cell transplantation for lymphoma. Semin Oncol 31(1):22–26

    Article  PubMed  Google Scholar 

  16. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC et al (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111(2):558–565

    Article  CAS  PubMed  Google Scholar 

  17. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA et al (1988) Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6(10):1562–1568

    CAS  PubMed  Google Scholar 

  18. Hirt C, Schuler F, Dolken L, Schmidt CA, Dolken G (2004) Low prevalence of circulating t(11;14)(q13;q32)-positive cells in the peripheral blood of healthy individuals as detected by real-time quantitative PCR. Blood 104(3):904–905

    Article  CAS  PubMed  Google Scholar 

  19. Schuler F, Dolken SC, Hirt C, Dolken MT, Mentel R, Gurtler LG et al (2006) No evidence for simian virus 40 DNA sequences in malignant non-Hodgkin lymphomas. Int J Cancer 118(2):498–504

    Article  PubMed  Google Scholar 

  20. Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH et al (2008) Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 14(4):418–425

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K et al (2010) Outcome following reduced-intensity allogeneic stem cell transplantation (RIC alloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 16(10):1419–1427

    Article  PubMed  Google Scholar 

  22. Ganti AK, Bierman PJ, Lynch JC, Bociek RG, Vose JM, Armitage JO (2005) Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 16(4):618–624

    Article  CAS  PubMed  Google Scholar 

  23. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A et al (2003) Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21(23):4407–4412

    Article  CAS  PubMed  Google Scholar 

  24. Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT et al (2004) Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104(12):3535–3542

    Article  CAS  PubMed  Google Scholar 

  25. Le Gouill S, Kroger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I et al (2012) Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 23(10):2695–2703

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We wish to thank Kerstin Gumm, Ute Pett, Berit Riemer and Maria Waterstradt for their excellent assistance.

Conflict of interest

No author has declared any conflict of interest.

Author information

Authors and Affiliations

  1. Department of Internal Medicine C—Haematology and Oncology, Stem Cell Transplantation, Ernst-Moritz-Arndt-University, Ferdinand-Sauerbruch-Straße, 17475, Greifswald, Germany

    William H. Krüger, Carsten Hirt & Gottfried Dölken

  2. Department of Haematology/Oncology, University Hospital Leipzig, Leipzig, Germany

    Nadezda Basara & Dietger Niederwieser

  3. Department of Haematology and Oncology, Clinic for Internal Medicine II, University Hospital Jena, Jena, Germany

    Herbert G. Sayer

  4. Department of Haematology/Oncology, Martin Luther University, Halle (Saale), Germany

    Gerhard Behre

  5. Department of Haematology/Oncology, Otto von Guericke University, Magdeburg, Germany

    Thomas Fischer

  6. Dietrich Bonhoeffer Hospital, Neubrandenburg, Germany

    Norbert Grobe

  7. Hospital Ernst von Bergmann, Potsdam, Germany

    Georg Maschmeyer

Authors
  1. William H. Krüger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carsten Hirt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nadezda Basara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Herbert G. Sayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gerhard Behre
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Thomas Fischer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Norbert Grobe
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Georg Maschmeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dietger Niederwieser
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Gottfried Dölken
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William H. Krüger.

Additional information

William H. Krüger and Carsten Hirt contributed equally to the paper.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Krüger, W.H., Hirt, C., Basara, N. et al. Allogeneic stem cell transplantation for mantle cell lymphoma—final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO). Ann Hematol 93, 1587–1597 (2014). https://doi.org/10.1007/s00277-014-2087-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-014-2087-z

Keywords

Search

Navigation